<DOC>
	<DOC>NCT02896920</DOC>
	<brief_summary>This study assesses Humira's速 real-life effectiveness in the management of dermatological manifestations of moderate to severe Hidradenitis Suppurativa (HS).</brief_summary>
	<brief_title>Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness</brief_title>
	<detailed_description />
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Has a clinical diagnosis of moderate to severe HS according to the treating physician judgment Need a change in ongoing therapy for any reason, but not limited to inadequate response, intolerance, suboptimal compliance, or patient preference. Patient will be approached to participate in the study after a decision to change patient's therapy for Humira速 is made by the treating physician. Has provided written informed consent (Patient Authorization) for participation in the study Is participating in a clinical interventional study Was treated with Humira速, or any other biologic agents for HS prior to baseline visit Has any other active skin disease or condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of HS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Humira速</keyword>
	<keyword>Hidradenitis Suppurativa (HS)</keyword>
	<keyword>Canada</keyword>
</DOC>